News

XENOTHERA Welcomes the National Academy of Medicine’s Call for a National Xenotransplantation Plan and Reaffirms Its Commitment to This Breakthrough Medical Innovation

May, 2025. XENOTHERA, a French biotechnology company based in Nantes and a pioneer in the development of genetically modified pigs for therapeutic purposes, welcomes the publication of the National Academy of Medicine's report…

XENOTHERA reaches important milestones in its oncology and onco-hematology clinical trials.

December, 2024. XENOTHERA reaches important milestones in its oncology and onco-hematology clinical trials….

XENOTHERA successfully secures €4 Million non-dilutive financing from the France 2030 Public Investment Plan for its LIS22 treatment for peripheral T-Cell lymphoma.

November, 2024. The PALT24 project (Polyspecific Antibodies in Lymphoproliferative T cell disorders) targets a critical onco-hematological disease with a notably low prognosis.

XENOTHERA presents XON11, a new hope for the treatment of pancreatic cancer

October, 2024. At the 36th ENA - EORTC - AACR symposium, Firas Bassissi, XENOTHERA CSO, presented highly promising results in pancreatic cancer.

XENOTHERA ANNOUNCES THE RECRUITMENT OF THE FIRST PATIENT OF THE PALT1 TRIAL IN PERIPHERAL T-CELL LYMPHOMA (PTCL) AND ITS ORPHAN DRUG STATUS (ODD) BY THE EMA

August 24. Treatment with its antibody directed against tumor lymphocytes offers new hope for patients with PTCL

[Press Release] New hope for patients: XENOTHERA granted orphan drug designation (ODD ) from the FDA for LIS1 in the treatment of T-lymphomas.

September 12, 2023. # Download our press release (english version) # Télécharger...

[Press Release] XENOTHERA strengthens its management team and governance.

June 8, 2023. # Download our press release (english version) # Télécharger...

[Press Release] XENOTHERA publishes its results at the World Cancer Congress in Chicago (ASCO) June 2-6, 2023.

May 30, 2023. # Download our press release (english version) # Télécharger...

[Communiqué officiel] À l’occasion du déplacement du Président de la République française, Emmanuel Macron, XENOTHERA est présente en Chine pour suivre un programme Business organisé par Business France.

April 5,2023. # Télécharger notre communiqué de presse (version française)

[Press Release] The French biotech XENOTHERA, on a mission with business France in China

April 3, 2023. # Download our press release (english version) # Télécharger...

[Press Release] XAV-19, the anti-SARS-CoV-2 GH-pAb of XENOTHERA best-in-class against all variants including BQ. 1.1

January 05,2023. # Download our press release (english version)

[Press Information] Orphan designation by the European Medicines Agency for LIS1, the transplant induction therapy from XENOTHERA

July 11th, 2022. # Download our press information (english version) # Télécharger...

[Press Information] Orphan designation by the European Medicines Agency for LIS1, the transplant induction therapy from XENOTHERA

July 11th, 2022. # Download our press information (english version) # Télécharger...

[Press Information] XENOTHERA presents LIS1 results at the American Transplant Congress (ATC) in Boston

May 2022. # Download our press information (english version) # Télécharger notre...

[Press Alert] Safety and efficacy results of LIS1

June 2022. # Download our press information (english version) # Télécharger notre...

XENOTHERA Welcomes the National Academy of Medicine’s Call for a National Xenotransplantation Plan and Reaffirms Its Commitment to This Breakthrough Medical Innovation

XENOTHERA reaches important milestones in its oncology and onco-hematology clinical trials.

XENOTHERA successfully secures €4 Million non-dilutive financing from the France 2030 Public Investment Plan for its LIS22 treatment for peripheral T-Cell lymphoma.

XENOTHERA presents XON11, a new hope for the treatment of pancreatic cancer

XENOTHERA ANNOUNCES THE RECRUITMENT OF THE FIRST PATIENT OF THE PALT1 TRIAL IN PERIPHERAL T-CELL LYMPHOMA (PTCL) AND ITS ORPHAN DRUG STATUS (ODD) BY THE EMA

XENOTHERA publishes the clinical efficacy of XAV-19, its anti-COVID antibody, in Frontiers in Immunology

Reflections on #AACR2024: our key insights and contributions

XENOTHERA announces the start of the second dose cohort in the FIPO trial

XENOTHERA : publication of the first-in-human trial of LIS1 in Solid Organ Transplantation

[Press Release] XENOTHERA recruits the first patient in the clinical trial of XON7, its new anti-cancer treatment

[Press Release] French biotech announces its therapeutic potential for oxygen-free patients

[Press Release] New hope for patients: XENOTHERA granted orphan drug designation (ODD ) from the FDA for LIS1 in the treatment of T-lymphomas.

[Press Release] XENOTHERA strengthens its management team and governance.

[Press Release] XENOTHERA publishes its results at the World Cancer Congress in Chicago (ASCO) June 2-6, 2023.

[Communiqué officiel] À l’occasion du déplacement du Président de la République française, Emmanuel Macron, XENOTHERA est présente en Chine pour suivre un programme Business organisé par Business France.

[Press Release] The French biotech XENOTHERA, on a mission with business France in China

[Press Release] XAV-19, the anti-SARS-CoV-2 GH-pAb of XENOTHERA best-in-class against all variants including BQ. 1.1

[Press Information] Orphan designation by the European Medicines Agency for LIS1, the transplant induction therapy from XENOTHERA

[Press Alert] XENOTHERA announces the efficacy of its XAV-19 antibody against the BQ.1.1variant.

[Press Release] XAV-19: end of EUROXAV clinical trial and positive trends for the XENOTHERA antibody.

[Newsletter] XENONEWS

[Press Information] Orphan designation by the European Medicines Agency for LIS1, the transplant induction therapy from XENOTHERA

[Press Information] XENOTHERA presents LIS1 results at the American Transplant Congress (ATC) in Boston

[Press Alert] Safety and efficacy results of LIS1